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Abstract
Background: PIK3CA is one of the genes most frequently mutated in human cancers and it is a potential target for 
personalized therapy. The aim of this study was to assess the frequency and type of PIK3CA mutations in gastric 
carcinoma and compare them with their clinical pathological correlates.
Methods: We analysed 264 gastric cancers, including 39 with microsatellite instability (MSI), for mutations in the two 
PIK3CA hotspots in exons 9 and 20 by direct sequencing of DNA obtained from microdissected cancer cells.
Results: The cases harbouring mutations were 42 (16%). All were heterozygous missense single base substitutions; the 
most common was H1047R (26/42; 62%) in exon 20 and the second was Q546K (4/42; 9.5%) in exon 9. All the mutated 
MSI cases (8/39) carried the H1047R mutation. No other association between PI3KCA mutations and their clinical 
pathological covariates was found. A metanalysis of the mutations occurring in the same regions presented in 27 
publications showed that ratio between exon 20 and exon 9 prevalences was 0.6 (95% CI: 0.5 -0.8) for colon, 1.6 (95% CI: 
1.1 -2.3) for breast, 2.7 (95% CI: 1.6 -4.9) for gastric and 4.1 (95% CI: 1.9 -10.3) for endometrial cancer.
Conclusions: The overall prevalence of PIK3CA mutations implies an important role for PIK3CA in gastric cancer. The 
lack of association with any clinical-pathological condition suggests that mutations in PIK3CA occur early in the 
development of cancer. The metanalysis showed that exon-selectivity is an important signature of cancer type 
reflecting different contexts in which tumours arise.
Background
Gastric cancer is the second cancer cause of death in the
world, although its incidence has declined in Western
countries. Despite advances in its molecular character-
ization, to date, the only effective treatment is surgery
with curative intent and the median 5-year survival is
25% [1].
Sporadic gastric cancer may arise along two major
molecular pathways: one involves gross chromosomal
alteration with multiple losses and gains of large chromo-
somal regions; the second is characterized by widespread
somatic alterations in simple repetitive genomic
sequences (microsatellites), as a result of defective DNA
mismatch repair complex. These latter are defined micro-
satellite unstable tumors (MSI), represent about 15% of
all the gastric tumors and are associated with a more
favorable prognosis, larger size, female gender, advanced
age, less lymph node involvement, intestinal histotype
and antral location [2]. Common alterations found asso-
ciated with MSI include promoter methylation of MLH1
[3] and mutations of TGFBR2, IGFR2 and BAX [4].
Microsatellite stable (MSS) gastric neoplasms show a
different set of alterations: several proto-oncogenes,
including MET, FGFR2 and ERBB2, are frequently ampli-
fied [5] while inactivation of both alleles of TP53 by loss
of heterozygosity and mutation is the most frequent
genetic event associated with MSS phenotype [6]. More-
over, loss of TP73, APC, DCC, FHIT and TFF1 are also
frequently detected [5,7].
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PIK3CA is a gene that encodes for the p110-alpha sub-
unit of phosphoinositide-3-kinase (PI3K). Recently, a key
role as oncogene is emerging for PIK3CA, as it is one of
the genes most frequently hit by somatic mutations in
several types of human cancer [8,9]. PI3K is part of a fam-
ily of ser-thr-kinases that interacts with phosphati-
dylinositol bisphosphate (4,5-PIP2) to produce the
phosphatidylinositol trisphosphate (3,4,5-PIP3), a second
messenger with several functions. PIP3 mainly binds the
plekstrine homology (PH) domain of a number of target
molecules and leads to their activation through cell mem-
brane targeting or modulation of their activity. One of the
best characterized targets of PI3K lipid products is the
protein kinase Akt. PI3K/Akt activation was demon-
strated to be involved in the regulation of several cellular
functions like cell survival, cell growth and angiogenesis
stimulation, inhibition of apoptosis, translation of several
proteins and hence, in the development of cancer [10,11].
Of the twenty exons that compose the PIK3CA gene,
more than 75% of the mutations are found in two hot-
spots located in exons 9 and 20, which encode for the
helical and kinase domains, respectively [8]. Expression
of the most common variants (E542K, E545K and
H1047R) is associated with an increased lipid kinase
activity and is oncogenic both in cell coltures and in vivo
[12,13]. Mutations affecting the two hot-spots have
recently been demonstrated to be functionally different
[14] and their respective rates of mutation have been
often reported as associated to specific cancer types or
particular patient features [15,16].
In this study, we analysed 264 gastric cancers for the
presence of mutations in the exons 9 and 20, by means of
direct sequencing, and correlated the presence of muta-
tions with clinical-pathological features, including MSI
phenotype. In addition, we compared the prevalence of
mutations occurring in the two exons with other studies
investigating primary specimens of human cancer.
Methods
Patients and samples
Our study included 264 consecutive cases of advanced
gastric cancer obtained from patients undergoing surgi-
cal intervention between 1989 and 2003 at the University
of Verona. All patients were treated by radical surgical
removal with resection margins free of microscopic dis-
ease and did not receive pre- or postoperative chemo- or
radiotherapy. Histological classification was according to
Laurén and the unified 1997 TNM system for gastric car-
cinoma was used for pathological staging. The clinical
pathological features of the series are detailed in Table 1.
This study was presented, reviewed and approved by the
Local Ethics Committee of the Verona Hospitals Concern
to include samples used for this analysis. Tumor samples
were obtained with informed consent from the insititu-
tions that provided the materials.
Mutation analysis
Normal and tumor DNA was extracted from manually
microdissected paraffin-embedded tissues as described
[17]. Mononucleotide microsatellites BAT25 and BAT26
(located in introns of the MSH2 and KIT genes, respec-
tively) were examined by PCR amplification using fluo-
rescent dye-labeled primers as described [18]. PCR
amplification and sequencing of PIK3CA exons 9 and 20
have been performed as described [19], using the follow-
ing primers Exon9_Forward: GGGAAAAATATGACAA
AGAAAGC; Exon9_Reverse: CTGAGATCAGC CAAAT
TCAGTT; Exon9_Sequencing: TAGCTAGAGACAAT-
GAATTAAGGGAAA-3; Exon20_Forward: CTCAATGA
TGCTTGGCTCTG; Exon20_Reverse: TGGAATC CAG
AGTGAGCTTTC; Exon20_Sequencing: TTGATGACAT
TGCATACATTCG.
Sequence differences from the NCBI reference
sequence were identified via manual inspection of aligned
electropherograms assisted by the Mutation Surveyor
software package (SoftGenetics, State College, PA).
Meta-analysis
To investigate the pattern of PIK3CA mutations in other
studies involving gastric as well as other cancer types, we
analysed the prevalence of PIK3CA  mutations in data
already present in literature and/or the COSMIC data-
base [20]. The steps performed to search, select papers
and collect data are detailed in Additional File 1. The full
list of references of included studies is provided in Addi-
tional File 2.
Statistical analysis
For meta-analysis, pooled prevalence estimates, preva-
lence ratios and confidence intervals were calculated
using fixed-effects Poisson regression, adjusted for the
number of cases analyzed per study. Prevalences and con-
fidence intervals of single studies were evaluated using
Clopper and Pearson method [21]. Correlation of the
presence of the H1047R mutation with clinical-pathologi-
cal features, p-values and confidence intervals were eval-
uated by means of logistic regression analysis.
Correlation with survival was evaluated by means of log-
rank test. For Cox multivariate regression, we selected the
most informative variables among the models that
included mutational status, using a 'forward' stepwise
method. A p-value less than 0.05 was considered signifi-
cant. For all the calculations and illustrations the R statis-
tical software package was used [22].
Results
We analysed the sequences of exons 9 and 20 of the
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and frequency of mutations found are detailed in Table 2.
A total of 42 cases (15.9%; 95% CI 11.7% - 20.9%) har-
bored at least one mutation in the regions analyzed. All
the mutations found were heterozygous missense single
base substitutions. The most common mutation was
H1047R occurring at the active site of the kinasic domain
in exon 20 and representing 62% of all the mutations. The
second most common mutation was Q546K that involves
an aminoacid change in the helicase domain in exon 9
and represents 9.5% of all the mutations found.
We found two missense mutations namely T1052I and
T1053I that were never reported before. The mutations
were confirmed using a second pair of primers (see Addi-
tional File 1). Both mutations involve an aminoacidic
change from threonin to isoleucin that implies a change
in the hydrophobic properties of the residues and may
potentially affect the protein function. One case har-
boured two mutations namely E545K and L1067F, in
exons 9 and 20, respectively.
In our series, MSI cases only harbored the H1047R
mutation. H1047R was, in fact, observed in 8 of 39 MSI
cases and was significantly associated with MSI status
(OR 3.0; 95% CI 1.0 - 7.9; Fisher's test P = 0.035). The
presence of mutation H1047R did not correlate with
either survival or other clinical pathological features gen-
erally associated with MSI, possibly due to the small
number of cases harboring the mutation. Furthermore,
we did not observe any significant association between
the presence of mutation and survival when considering
MSI cases only. In addition, we did not find any correla-
tion with clinical pathological features when considering
the presence of mutations in both exons (Table 3) or in
exon 9 and 20 separately. A multivariate survival analysis
was performed in order to evaluate the effect of the pres-
ence of mutation together with other clinical-pathologic
variables (Table 4). After selection of the best model,
TNM stage, age and tumor location were significantly
associated with survival, whereas only a marginal effect
was observed for MSI status.
In order to systematically compare our results with the
available literature for stomach and other cancer types,
we selected 38 series described in 27 papers analyzing
mutations in the PIK3CA locus in primary cancer sam-
ples (the full list of references is provided in Additional
File 2). We limited the analysis to the mutations occur-
ring at the aminoacids 542-549 and 1043-1048, of exons 9
a n d  2 0 ,  r e s p e c t i v e l y ,  t h a t  w e r e  a n a l y z e d  i n  c o m m o n
between the series. These regions contain the large
majority of mutations observed in PIK3CA [8].
The prevalence of mutations in exons 9 and 20 for each
series is represented in Figure 1. Although the overall
rates of mutation was variable among the series, even of
the same cancer type, the rates of mutation in exon 9 and
20 significantly correlated to each other (Spearman's ρ =
0.75, P-value < 0.001), suggesting that the ratio between
exon 9 and exon 20 mutations is dependent on the cancer
type. Therefore, we evaluated the pooled ratio of preva-
lence between exon 20 and 9 in different studies grouped
by cancer type, by means of Poisson regression analysis.
Results are shown in Table 5. For breast cancer, given the
large number of studies reported, we divided the series
according to the histotype (ductal and lobular), where the
information was available, and categorized the remainder
series as breast cancer with histotype unspecified.
Among series of ductal histotype, prevalence of muta-
tions was significantly biased towards exon 20, whereas a
marginally significant preference for exon 9 was observed
Table 1: Clinical features of 264 cases of gastric cancers 
analyzed for mutations in PI3KCA.
Parameter Categories Frequency
Gender F 89 (33.7%)
M 175 (66.3%)
Age mean (sd) 67.4 (11.2)
Lauren Intestinal 170 (65.4%)
Mixed 27 (10.4%)
Diffuse 63 (24.2%)
pT 2 99 (37.4%)
3 129 (48.7%)
4 36 (13.6%)
pN 0 53 (20.2%)
1 100 (38.0%)
2 80 (30.4%)
3 30 (11.4%)
pM 0 215 (87.4%)
1 31 (12.6%)
Tumor Location Antrum 107 (40.5%)
Body 72 (27.3%)
Fundus 69 (26.1%)
Linitis 12 (4.5%)
Gastric stump 4 (1.5%)
MSI MSI 39 (14.8%)
MSS 225 (85.2%)Barbi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:32
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for lobular histotype series (see Table 5 and Figure 1). The
studies on colon cancer showed a significantly increased
prevalence of mutations in exon 9 with all the series hav-
ing a similar mutational pattern. Tumors of the endome-
trium were significantly more hit by mutations affecting
exon 20. For gastric cancer, the present series as well as
the series reported by Samuels showed a greater preva-
lence of exon 20, whereas the remainder series showed
little or no difference between exons.
Discussion
The aim of this study was to characterize the mutational
status of PIK3CA in a large series of gastric cancers in
order to determine its prevalence with an adequate preci-
sion and to correlate it with clinical-pathological features.
The overall prevalence of mutations was 15.9%, a value
that is within the range of the currently available litera-
ture [8,23-25], nonetheless the prevalences observed in
different series are heterogeneous, ranging from 4.5% to
25%. Reasons for such a heterogeneity may be due to spe-
cific interactions of the mutations with environmental
and genetic backgrounds, although experimental factors
can not be excluded.
To our knowledge, the mutations involving aminoacids
1052 and 1053 (T1052I and T1053I) were never pub-
lished before, nor are described in the COSMIC database,
despite the large number of studies investigating the
region. As the mutations imply a change in the hydropho-
bicity of the aminoacidic residue, a functional role cannot
be excluded. The mutations were found in MSS cases that
did not show any particular feature.
We also found that the most common PIK3CA muta-
tion (H1047R) was significantly associated with MSI phe-
notype. The association is moderate and would benefit
from confirmation on an indipendent series. An associa-
tion between PIK3CA  mutations and MSI has been
reported or at least suggested in both colon and stomach
cancer [8,23,24,26]. At variance with our findings, in the
two studies regarding gastric cancer and reporting muta-
tions by MSI status, exon 9 and exon 20 mutations were
evenly distributed between the subtypes [23,24]. How-
ever, the small number of mutated MSI cases prevents
statistical comparison. The fact that only one type of
mutation was found in our series of MSI tumors is not
surprising as the narrow spectrum of alterations of MSI
gastric tumors may, in turn, restrict the type of PIK3CA
mutations that are oncogenic in that context.
Despite the large series analyzed, we did not find any
correlation of PIK3CA mutations with clinical pathologi-
cal features of gastric cancers apart from the association
between MSI and H1047R. The lack of associations sug-
gests that alteration of PIK3CA is an event that occurs
early in a subset of gastric cancers that progresses
towards malignancy through other mechanisms. In fact,
Table 2: Frequency of PI3KCA mutations found in 264 gastric cancers, by mutation type.
Mutation Overall frequency
(MSI only)
Percent/total cases Percent/mutated 
cases
Exon 9 E542K 2 0.76% 4.76%
E545K 2 0.76% 4.76%
Q546K 4 1.52% 9.52%
Total Mutations (ex. 9) 8 3.03%
Exon 20 M1043V 1 0.38% 2.38%
H1047R 26 (8) 9.85% 61.90%
H1048T 1 0.38% 2.38%
G1050D 2 0.76% 4.76%
T1052I 1 0.38% 2.38%
T1053I 1 0.38% 2.38%
D1056N 2 0.76% 4.76%
L1067F 1 0.38% 2.38%
Total Mutations (ex.20) 35 13.26%
Total Mutations 42 15.91%Barbi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:32
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in a multivariate survival model there was no evident
effect of the presence of mutation on prognosis.
Based on our meta-analysis, the ratio between muta-
tion prevalences in exons 9 and 20 can be generally con-
sidered a signature of cancer type. In particular, we found
a significant exon bias for colon cancer, breast cancer
with ductal histotype and endometrium cancer. In colon
cancer, exon 9 is significantly more hit than exon 20. This
confirms suggestions from previous studies [8,23,27]. The
opposite mutational pattern was consistently found in
studies regarding endometrial cancer with exon 20 largely
more hit than exon 9. This peculiarity was already
pointed out and suggests a specific mechanism of
PI3KCA involvement for endometrial cancer [28-30].
Table 3: Distribution of Clinical-pathological covariates according to the presence of PI3KCA mutations in 264 gastric 
cancers.
Parameter Categories Wt Mutated Odds Ratio
(95% CI)
P
Gender F 74 (83.1%) 15 (16.9%) 1 0.766
M 148 (84.6%) 27 (15.4%) 0.9 (0.5 - 1.8)
Age mean 67.47 66.81 0.771
pT 2 88 (88.9%) 11 (11.1%) 1 0.077
3 108 (83.7%) 21 (16.3%) 1.6 (0.7 - 3.5)
4 26 (72.2%) 10 (27.8%) 3.1 (1.2 - 8.1)
pN 0 42 (80.8%) 10 (19.2%) 1 0.840
1 86 (86.0%) 14 (14.0%) 0.7 (0.3 - 1.7)
2 67 (83.8%) 13 (16.2%) 0.8 (0.3 - 2.1)
3 26 (86.7%) 4 (13.3%) 0.6 (0.2 - 2.2)
pM 0 182 (85.0%) 32 (15.0%) 1 0.298
1 24 (77.4%) 7 (22.6%) 1.7 (0.6 - 4.0)
Lauren Intestinal 147 (86.5%) 23 (13.5%) 1 0.275
Mixed 22 (81.5%) 5 (18.5%) 1.5 (0.5 - 4.0)
Diffuse 49 (77.8%) 14 (22.2%) 1.8 (0.9 - 3.8)
Location Antrum 93 (86.9%) 14 (13.1%) 1 0.394
Body 58 (79.5%) 15 (20.5%) 1.7 (0.8 - 3.9)
Fundus 59 (85.5%) 10 (14.5%) 1.1 (0.5 - 2.7)
Grading G1 13 (86.7%) 2 (13.3%) 1 0.652
G2 76 (87.4%) 11 (12.6%) 0.9 (0.2 - 6.5)
G3 117 (83.0%) 24 (17.0%) 1.3 (0.3 - 8.9)
Microsatellite 
instability
MSI 31 (79.5%) 8 (20.5%) 1 0.408
MSS 191 (84.9%) 34 (15.1%) 0.7 (0.3 - 1.7)
Survival rate at 2 
years (95% CI)
46.7% (40.5%-
53.9%)
46.9% (32.4%-
67.8%)
0.941Barbi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:32
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It is less clear whether an exon bias exists in breast can-
cer as many studies are apparently contradictory (see Fig-
ure 1). However, for studies that did furnish the
information about the histotype of each sample, we
observed a different exon preference between lobular and
ductal histotypes as already suggested [15]. For ductal
histotype, exon 20 was significantly more hit compared to
exon 9, whereas a slight but inverse tendency was found
in series of lobular breast cancers. This pattern is not evi-
dent in studies where the information about histotype is
Table 4: Multivariate Cox survival analysis of 245 gastric cancer patients.
Parameter Category HR (95% CI) P-Value
PI3KCA status wt 1.0 0.630
mutated 1.1 (0.7-1.7)
Stage I 1.0 <0.001
II 3.1 (1.1-9.1)
III 11.6 (4.2-31.8)
IV 19.1 (6.8- 53.2)
Age (10 years increment) 1.3 (1.1-1.5) <0.001
Tumor Location Antrum 1.0 0.004
Body 1.1 (0.7-1.5)
Fundus 1.8 (1.3-2.6)
MSI status MSI 1.0 0.077
MSS 1.7 (0.9-3.0)
Table 5: Overall frequency and pooled prevalence ratio of mutations affecting the two hot spots of PIK3CA located in Exon 
9 and exon 20 in 36 series grouped by cancer type
Tumor Type nr. series total cases Exon 9 Exon 20 Ex20/Ex9
Prevalence 
Ratio
(95% CI)
P-value
Breast Cancer
(histotype not
specified)
6 788 101 105 1.0 (0.8 -1.4) 0.7805
Breast Cancer
(lobular
histotype)
4 99 25 15 0.6 (0.3 -1.1) 0.1178
Breast Cancer
(ductal
histotype)
5 499 41 64 1.6 (1.1 -2.3) 0.0260
Endometrial
Cancer
5 263 7 29 4.1 (1.9 -10.3) 0.0007
Colon Cancer 6 1292 134 80 0.6 (0.5 -0.8) 0.0003
Gastric Cancer 5 602 17 46 2.7 (1.6 -4.9) 0.0005
Head and Neck
squamous
Cancer
3 175 7 2 0.3 (0.0 -1.2) 0.1182
Glioblastoma 4 203 3 5 1.7 (0.4 -8.1) 0.4842Barbi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:32
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not available, possibly as an result of mixing different
kinds of tumours together.
For squamous head and neck tumors a slight tendency
to a greater prevalence of exon 9 mutations was observed
among series, although the low incidence of PIK3CA
mutations in this kind of neoplasm has probably pre-
vented this tendency to stand out. For glioblastoma, there
was no evidence of exon-selectivity, due to the fact that a
high percent of non hot-spot mutations are frequently
found in this disease [8,31].
Finally, in stomach cancer series, exon 20 resulted to be
more involved than ex on 9, although a common trend
among the series was substantially missing. The hetero-
geneity in both overall prevalence and exon-selectivity in
stomach cancer may be due to the strong influence that
specific etio-pathologic, genetic and environmental fac-
tors have on this disease.
Although several of the observations presented in our
meta-analysis were sporadically suggested or demon-
strated in single papers, this approach allows to gather
more convincing evidences by pooling similar studies.
Moreover, the meta-analysis has the further advantage of
providing an outlook and an estimate of PIK3CA exon-
selectivity and standardized rate of mutation in different
cancer types, although this might be affected by the limi-
tations derived from retrospective studies.
The association of specific mutations with either can-
cer type or subtype is in line with recent findings about
different mechanisms through which these mutations
exert their oncogenic potential. In fact, it has been shown
that mutations occurring at the kinasic domain are
dependent upon binding with p85, another component of
PI3K, to be fully oncogenic, whereas mutations in the
helical domain are dependent upon RAS-GTP binding
[14]. The dependence of PIK3CA mutations on other sig-
nalling components is in keeping with the fact that the
genetic background in which tumours develop may
require and select specific altered activities of p110-
alpha.
Conclusions
We found a relatively high prevalence of PIK3CA somatic
mutations further supporting the role of PIK3CA  as a
major oncogene in gastric cancer. Such prevalence was
highly biased towards exon 20, in particular, in MSI cases
which seem to carry only one type of exon 20 mutations.
By analysis of the mutations occurring in the two stan-
dard hot-spot regions of PIK3CA in 27 published papers
on six major cancer types (colorectal, breast ductal,
b r e a s t  l o b u l a r ,  s t o m a c h ,  e n d o m e t r i u m ,  h e a d  a n d  n e c k
and glioblastoma), we found that exon-selectivity is an
important signature of cancer type and subtype reflecting
different contexts in which tumours arise.
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